Cogstate Limited (ASX:CGS), a global leader in clinical trial endpoint data quality and digital cognitive assessments, today releases its Appendix 4E and Annual Report for the year ended 30 June 2025 (“FY25”). The Company has delivered a year of record operational and financial performance highlighting Cogstate’s scalable business model, increasing clinical trials demand, and continued innovation in brain health measurement.